Werewolf Therapeutics IncHOWL
Price$0.92

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$34.6MTTM through 30 Jun 2026
Free Cash Flow -$30.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-212.5%ROE
-143.3%ROA

Balance Sheet Health

Current Ratio2.91x
Net Debt-$28.8Mnet cash position
Cash & Equivalents$22M

Quality Metrics

Altman Z-Score-28.01
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$0.73TTM
'20'21'22'23'24'25
FY2025: $-1.30

Dividend

No dividend

Capital Allocation

R&D Spend$32.9M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.